AstraZeneca and Ardelyx announce worldwide licensing deal
8 October 2012 | By AstraZeneca
AstraZeneca and Ardelyx announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme...
List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
8 October 2012 | By AstraZeneca
AstraZeneca and Ardelyx announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme...
19 September 2012 | By Bristol-Myers Squibb
New non-profit organization to speed pharmaceutical R&D...
12 September 2012 | By AstraZeneca
AstraZeneca PLC has conducted a successful global bond market transaction issuing a total of $2 billion of notes...
3 September 2012 | By Pradeep Sharma and Katherine Fenner, Global DMPK, AstraZeneca R&D
Physiologically based pharmacokinetic (PBPK) models describe the different compartments (tissues) in the body linked via arterial and venous blood flow (Figure 1). The volume of each tissue and blood flows are available from literature data1-5 and PBPK models have been developed for many species including rat, mouse, dog, pig and…
AstraZeneca today announced that Pascal Soriot has been appointed as the company’s Chief Executive Officer. Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
28 August 2012 | By AstraZeneca
European Commission approves ZINFORO™...
13 August 2012 | By AstraZeneca
NEXIUM 20mg retail launch targeted for 2014, subject to regulatory approval...
9 August 2012 | By AstraZeneca
AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals...
30 July 2012 | By Bristol-Myers Squibb
Bristol-Myers Squibb and AstraZeneca announced the results of analyses...
16 July 2012 | By AstraZeneca
AstraZeneca reported on the remuneration arrangements relating to David Brennan’s retirement...
6 July 2012 | By Abbott
Groundbreaking partnership that aims to speed the discovery of essential new treatments...
6 July 2012 | By AstraZeneca
AstraZeneca has completed the previously indicated sale of the assets of its subsidiary, Aptium Oncology...
30 June 2012 | By AstraZeneca
Bristol-Myers Squibb to acquire Amylin...
27 June 2012 | By AstraZeneca
AstraZeneca and Merck have agreed to amend certain provisions of the agreements relating to the companies’ arrangements in the US...
22 June 2012 | By AstraZeneca
Zinforo receives positive CHMP opinion...